Clinical trial · Observational
Role of FGF21 in Breast Cancer
Role of Fibroblast Growth Factor 21(FGF21) in Breast Cancer
NCT07113418CI-TRIAL-00093353not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The present study aims to evaluate the serum level of FGF-21 in patients with breast cancer and its correlation with clinical, laboratory, and pathological data.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ELISA | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Breast cancer patients
- description
- Female patients admitted at south Egypt cancer institute who diagnosed as breast cancer based on full clinical, radiological and pathological data.
- interventionNames
- Diagnostic Test: ELISA
Primary outcomes (1)
- measure
- Serum FGF21 level measured by ELISA in breast cancer patients compared to healthy controls at enrollment.
- timeFrame
- At enrollment
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria:Female patients admitted at south Egypt cancer institute who diagnosed as breast cancer basedon full clinical, radiological and pathological assays. \- Exclusion Criteria:Patients diagnosed with other concomitant cancers. \-
References
Publications (10)
- BACKGROUNDGliniak CM, Gordillo R, Youm YH, Lin Q, Crewe C, Zhang Z, Field BC, Fujikawa T, Virostek M, Zhao S, Zhu Y, Rosen CJ, Horvath TL, Dixit VD, Scherer PE. FGF21 promotes longevity in diet-induced obesity through metabolic benefits independent of growth suppression. Cell Metab. 2025 Jul 1;37(7):1547-1567.e6. doi: 10.1016/j.cmet.2025.05.011. Epub 2025 Jun 16. PMID 40527315
- BACKGROUNDCymbaluk-Ploska A, Gargulinska P, Chudecka-Glaz A, Kwiatkowski S, Pius-Sadowska E, Machalinski B. The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients. Diagnostics (Basel). 2020 Jun 18;10(6):414. doi: 10.3390/diagnostics10060414. PMID 32570721
- BACKGROUNDFerreira Almeida C, Correia-da-Silva G, Teixeira N, Amaral C. Influence of tumor microenvironment on the different breast cancer subtypes and applied therapies. Biochem Pharmacol. 2024 May;223:116178. doi: 10.1016/j.bcp.2024.116178. Epub 2024 Mar 30. PMID 38561089
- BACKGROUNDEwendt F, Feger M, Foller M. Role of Fibroblast Growth Factor 23 (FGF23) and alphaKlotho in Cancer. Front Cell Dev Biol. 2021 Jan 14;8:601006. doi: 10.3389/fcell.2020.601006. eCollection 2020. PMID 33520985
- BACKGROUNDPing Q, Yan R, Cheng X, Wang W, Zhong Y, Hou Z, Shi Y, Wang C, Li R. Cancer-associated fibroblasts: overview, progress, challenges, and directions. Cancer Gene Ther. 2021 Sep;28(9):984-999. doi: 10.1038/s41417-021-00318-4. Epub 2021 Mar 12. PMID 33712707
- BACKGROUNDSanchez-Hurtado LA, Tejeda-Huezo BC, Gomez-Flores SS, Esquivel-Chavez A, Cano-Oviedo AA, Baltazar-Torres JA. Elderly patients in a Mexican intensive care unit: A retrospective analysis. Med Intensiva (Engl Ed). 2018 May;42(4):258-260. doi: 10.1016/j.medin.2017.03.006. Epub 2017 May 12. No abstract available. English, Spanish. PMID 28502645
- BACKGROUNDGong X, Xiong H, Liu S, Liu Y, Yin L, Tu C, Wang H, Zhao Z, Chen W, Mei Z. Qingpeng Ointment Ameliorates Inflammatory Responses and Dysregulation of Itch-Related Molecules for Its Antipruritic Effects in Experimental Allergic Contact Dermatitis. Front Pharmacol. 2019 Apr 9;10:354. doi: 10.3389/fphar.2019.00354. eCollection 2019.